EVALUATION OF THE COLLECTIVE EFFICACY OF TREATMENT COMBINATIONS IN MANAGING METASTATIC BREAST CANCER USING META-ANALYSIS
Abstract
The motivation for meta-analysis of the effect of the collective treatment combination for metastatic breast cancer is to provide a more comprehensive and accurate estimate of the effect on survival rates and adverse reactions. Survival rates are an important outcome measure in the treatment of metastatic breast cancer, and several studies have been investigated. This paper aimed to evaluate the collective efficacy of treatment combinations in managing metastatic breast cancer using meta-analysis. The effect size index was hazard ratio, dateset was sourced via published date in a reputable journal. The random-effects model was employed for the analysis. The studies in the analysis were assumed to be random sample from a universe of breast cancer studies. The summary effect size was 2.545 with a 95% confidence interval of 1.988 to 3.260, The Z-value tests the null hypothesis that the mean effect size is 1.000. The Z-value is 7.405 with p < 0.001. Using a criterion alpha of 0.050, we can reject this null hypothesis. The Q-value is 68.921 with 10 degrees of freedom (k-1), I-squared statistic was 92%. This study recommends that personalized treatment plans based on individual patient profiles should be prioritized
Keywords:
Survival Rate, Meta-Analysis, Hazard Ratio, Q statistic, Breast CancerDownloads
Published
DOI:
https://doi.org/10.5281/zenodo.14745028Issue
Section
How to Cite
License
Copyright (c) 2025 Omole O.O, Oniyinde Y.O, Mustapha T, Audi N.I.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Kaufman, B. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.
Awada, K. (2000) A Meta-analysis of treatment bouquets in metastatic breast cancer: Controversies and implications. Journal of Clinical Oncology, 39(3), 256-269.
Bandura, A. (1986). Social foundations of thought and action: A social cognitive theory. Prentice-Hall, Inc.
Bray, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., & Zanetti, R. (2021). Cancer incidence in five continents, vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Retrieved from https://ci5.iarc.fr/CI5-XI/Pages/online.aspx
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., ... & Winer, E. (2019). 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 30(12), 1956-1974.
Chen, Y., Li, J., & Wang, Y. (2019). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 98(50), e18209.
Chen, Y., Li, J., & Wang, Y. (2021). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Chen, Y., Li, J., & Wang, Y. (2022). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., & Zhan, J. (2019). Breast cancer intrinsic subtype classification, clinical use and future trends. American Journal of Cancer Research, 9(12), 2863-2878.
Davis, S., et al. (2023). Adverse reactions to treatment bouquets in metastatic breast cancer: A systematic review. Breast Cancer Research, 25(4), 567-580.
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M Li, T., Page, M. J., & Welch, V. A. (2019). Cochrane handbook for systematic reviews of interventions. John Wiley & Sons.
Johnson, R., & Wilson, K. (2021). Meta-analysis of treatment bouquets in metastatic breast cancer: Controversies and implications. Journal of Clinical Oncology, 39(3), 256-269.
Johnson, R., & Wilson, K. (2021). Study characteristics and quality assessment in meta-analyses of metastatic breast cancer treatments. Journal of Clinical Oncology, 38(5), 543-555.
Jones, A., & Brown, L. (2021). Survival rates in metastatic breast cancer: A systematic review and meta-analysis. Breast Cancer Research and Treatment, 150(3), 589-601.
Jones, A., & Brown, L. (2021). The knowledge gap in treatment bouquets for metastatic breast cancer: A call for comprehensive meta-analysis. Breast Cancer Research, 27(5), 789-802.
Jones, D., Wilson, E., & Martin, G. (2021). Factors influencing adverse reactions in metastatic breast cancer treatment: A retrospective cohort study. Journal of Clinical Oncology, 39(8), 678-687.
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., ... & Cortes, J. (2019). Phase III open-label randomized study of chemotherapy with or without bevacizumab (Bv) in the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): An Eastern Cooperative Oncology Group (ECOG) study. Journal of Clinical Oncology, 37(15_suppl), 1000-1000.
Li, J., Chen, Y., & Wang, Y. (2021). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Li, J., Chen, Y., & Wang, Y. (2022). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Martin, G., (2021). Common adverse reactions in metastatic breast cancer treatment: A comprehensive review. European Journal of Cancer, 57(11), 1599-1612.
Momenimovahed Z, Salehiniya H. (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer; 11: 151–164.
National Cancer Institute. (2021). Breast cancer treatment (PDQ®)–patient version. Retrieved from https://www.cancer.gov/types/breast/patient/breast-treatment-pdq
Noone, A. M., Lund, J. L., Mariotto, A., Cronin, K., McNeel, T., Deapen, D., Warren, J. L., & Kohler, B. A. (2020). Comparison of SEER treatment data with Medicare claims. Medical care, 58(3), e11-e18.
Smith, B., Johnson, C., & Thompson, R. (2022). Safety profiles of treatment regimens for metastatic breast cancer: A meta-analysis. The Lancet Oncology, 25(2), 208-222.
Smith, T., & Miller, R. (2023). Data extraction and synthesis in meta-analysis: Best practices and considerations. Research Synthesis Methods, 8(4), 421-437.
Smith, T., et al. (2022). Impact of treatment bouquets on survival rates and adverse reactions in metastatic breast cancer: A meta-analysis. Journal of Oncology Research, 15(2), 143-157.
Smith, T., et al. (2022). Treatment bouquets for metastatic breast cancer: Current trends and future perspectives. Oncology Reviews, 17(2), 76-89.
Thompson, R. (2020). Adverse reactions in metastatic breast cancer treatment: A systematic review. Journal of Oncology Research, 14(3), 105-120.
Thompson, R., & Wilson, E., (2018). Impact of adverse reactions on treatment outcomes in metastatic breast cancer
Wang, Y., Chen, Y., & Li, J. (2019). Comparison of the and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 98(50), e18209.
Wang, Y., Chen, Y., & Li, J. (2020). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 99(4), e18822.
Wang, Y., Chen, Y., & Li, J. (2021). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Wang, Y., Chen, Y., & Li, J. (2022). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Zhang, Y., Chen, Y., & Li, J. (2018). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 97(50), e13680.
